Navigation Links
AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

I/II Study of Elotuzumab (Elo) plus Lenalidomide/Dexamethasone in Relapsed/Refractory (R/R) Multiple Myeloma: Updated Phase II results and Phase I/II long-term safety; S. Lonial, et al.; Abstract 8542; Poster Discussion Session; June 3, 2013; 1:15 p.m.-5:15 p.m.

ABT-888 (Veliparib)

  • A Phase I Study of Veliparib (ABT-888) in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors; K. M. Bell-McGuinn , et al.; Abstract 2485; Poster Discussion Session; June 3, 2013; 8:00 a.m.-11:45 a.m.

ABT-806

  • A phase I and Biodistribution Study of ABT-806i, an 111 Iindium-Labeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806; H.K. Gan , et al.; Abstract 2520; Poster Discussion Session; June 4, 2013; 8:00 a.m.-12:30 p.m.

About ABT-199

ABT-199 is a selective inhibitor of B-cell lymphoma-2 (BCL-2) proteins. The B-cell lymphoma 2 gene prevents apoptosis of some cells including lymphocytes, and can be highly expressed in cancers in the lymph nodes, spleen, and other organs of the immune system. As a BH3-mimetic, ABT-199 is designed to block the function of the BCL-2 protein by restoring the communication system that tells cancer cells to self-destruct. Jointly developed by AbbVie and Genentech, the companies are pioneering BCL-2 research with ABT-199, which is currently in Phase 1/1b clinical trials for the treatment of CLL, the most common leukemia in the United States, and several other cancers.

The U.S. Food and Drug Administration (FDA) recently accepted AbbVie's amended clinical trial protocols for studies of ABT-199 in patients with CLL and enrollment for ABT-199 clinical trials in CLL, NHL and multiple myeloma has been re-instated. AbbVie and Genentech expect to move ABT-199 into l
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
2. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
3. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
4. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
5. AbbVie Reports First-Quarter 2013 Financial Results
6. AbbVie to Host First-Quarter Earnings Conference Call
7. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
8. AbbVie to Present at Barclays Global Health Care Conference
9. AbbVie Issues Inaugural Full-Year Outlook for 2013
10. AbbVie Named to S&P 500 Dividend Aristocrat Index
11. Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... July 30, 2014   Unique Pizza and ... OTC Pink: UPZS), a Delaware Corporation, is pleased ... with Larasan Pharmaceutical Corporation ("Larasan"), a nature-based pharmaceutical company ... the agreement, US-based Larasan will work with Unique ... pizza through Larasan,s vast distribution network throughout ...
(Date:7/30/2014)... CLARA, Calif. , July 30, 2014 ... economy, released a study today that examines ... biopharma and medical device companies.  According to the annual ... saw the biggest potential returns since SVB started tracking ... year of the IPO.  Built on solid healthcare M&A ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3
... SAN BERNARDINO, Calif., Dec. 13, 2010 ... the nation, IEHP Medicare DualChoice (HMO SNP) is one of only ... its Part D quality and performance from the Centers for Medicare ... rating to gauge how well health and drug plans perform on ...
... FORT LAUDERDALE, Fla., Dec. 13, 2010 The creators of the ... are donating toys and a much needed medication management system ... Children,s Hospital at Broward General, in Fort Lauderdale, Florida. ... Smile, Inc. will be onsite Wednesday, December 15, from 1-3 ...
Cached Medicine Technology:IEHP Earns Highest Rating for Medicare Part D Quality and Performance 2Med Time Technology, Inc. Teams up with Give A Smile, Inc. to Provide Pill Timer™ Kits and Toys to Children and Parents at the Chris Evert Children's Hospital of Broward General 2
(Date:7/30/2014)... Decene is an alkene with the formula ... atoms with one double bond. 1-Decene enters all ... be used as a co-monomer in certain copolymers ... oxo alcohols, synthetic lubricants, synthetic fatty acids, and ... 10% customization on this report. , http://www.micromarketmonitor.com/contact/2523613387-request_for_customization.html ...
(Date:7/30/2014)... 2014 The Europe Phytochemicals & plant ... plant extracts market in Europe with analysis and forecast ... Europe is estimated to grow from around 710.18$ million ... CAGR of 8.4%, for the given period. , Browse ... extracts market report, to get an idea of the ...
(Date:7/30/2014)... diagnosed with depression as preschoolers are likely to suffer ... research shows. , Depressed preschoolers were 2.5 times more ... middle school than kids who were not depressed at ... School of Medicine in St. Louis. , Their study ... American Journal of Psychiatry . , "It,s the same ...
(Date:7/30/2014)... Bringing Disney Excellence to Central Iowa ... the Central Iowa Chapter of the Association for Talent ... renowned professional development course, “Disney’s Approach to Business Excellence,” ... world class workshop will inspire area professionals from businesses ... and satisfy customers. , “Disney 'magic' as I call ...
(Date:7/30/2014)... organs for transplants sounds like something out of a ... day make actual kidneys, livers, hearts and other organs ... journal Langmuir , scientists are reporting new understanding ... a step closer to realizing their goal of making ... and colleagues note that this idea of producing tissues ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3Health News:Central Iowa Chapter of ATD Hosts Exclusive Disney Institute for Central Iowa Businesses 2Health News:Central Iowa Chapter of ATD Hosts Exclusive Disney Institute for Central Iowa Businesses 3
... study finds , THURSDAY, Dec. 6 (HealthDay News) -- ... she receives surgery after a breast cancer diagnosis, U.S. ... Medical Institutions in Baltimore also found that a lengthy ... , Factors such as socioeconomic status and the cumulative ...
... 6 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced today ... treatment of chronic myelogenous leukemia,(CML) at the upcoming American Society ... held December 8th - 11th, 2007 in,Atlanta, Georgia., , ... listed below:, Date: ...
... 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical company ... cardiovascular, inflammatory and,metabolic diseases, today announced the appointment ... "We are very pleased to welcome Don ... operational insights will be of great benefit to ...
... New Product Name Also Unveiled in Ongoing ... Dec. 6 Favrille, Inc. (Nasdaq:,FVRL), a ... treatment of cancer, announced that new data,including ... 2 clinical,trial of Specifid(TM) (formerly FavId(R)), will ...
... US Oncology, the nation,s leading,oncology services company, today ... president and chief operating officer. The appointment,becomes effective ... operating experience, combined with his work in,large diversified ... Bruce Broussard, president of US Oncology.,"His proven success ...
... Wagoner on new data showing first increase in U.S.,teen ... that the,dramatic decrease in teen pregnancy rates in the ... a screeching halt. This unwelcome,development should not come as ... success over the last decade -- the decline in ...
Cached Medicine News:Health News:Black Women Wait Longer for Breast Cancer Surgery 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 3Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 4Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 3Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 4Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 5Health News:US Oncology Appoints Glen Laschober EVP & Chief Operating Officer 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: